NCT03461445View on ClinicalTrials.gov

Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions
Kidney Transplant; ComplicationsToxicityDrug ToxicityNeurotoxicity
Interventions
DRUG

Envarsus

Patients will be randomized to receiving Envarsus instead of IR Tacrolimus

DRUG

IR Tacrolimus

Patients will be randomized to receiving IR Tacrolimus instead of Envarsus

Trial Locations (1)

95817

UC Davis, Sacramento

Sponsors

Collaborators (1)

Veloxis Pharmaceuticals
All Listed Sponsors
collaborator

Veloxis Pharmaceuticals

INDUSTRY

lead

University of California, Davis

OTHER